Try GOLD - Free

Make In India' - A Major Boon To Medical Technology Industry

Bio Spectrum

|

November 2017

Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 165 countries for the last 20 years. Today, Trivitron Healthcare, through successful inorganic synergies with local and global firms, has a revenue turnover of Rs 750 crore. BioSpectrum India spoke to Dr GSK Velu, Chairman & Managing Director, Trivitron Healthcare Group of Companies to about the status of medical technology market in India and competition coming from Chinese medical devices.

Excerpts of the interview

Make In India' - A Major Boon To Medical Technology Industry

What is the current status of medical technology market in India?

The current med tech industry is driven by innovation and new technologies. With the advent of engineering innovations, recent development have led to low cost products that are at par with existing products on quality. The Medical technology market in India is growing at about 10-12 per cent. Domestic companies in India focus more on consumables, test kits and lower-value equipment. There lies a greater opportunity for indigenous solutions and domestic Medtech production. With the availability of advanced and sophisticated medical technology, there is a surge in creating new markets with an increased dependency by doctors on advanced medical devices leading to rapid de-generation of existing medical technology which is creating a demand for replacement and up gradation of many products.

How do you see the growth of the market in the coming years?

India’s healthcare system is paradoxical - on the one hand, it boasts of ‘best in class’ healthcare delivery attracting medical tourists from across the world, and on the other, it is characterized by a near absence of accessible, affordable quality health services for a large part of its population. Existing infrastructure, especially in smaller towns/ rural areas, is inadequate to meet the ever-growing needs of the Indian population. A transforming medical technology landscape, improving healthcare delivery and financing mechanisms, and changing patient profile are driving growth in the medical technology industry currently. With new rules coming into the scenario, the industry can use the ‘Make in India’ platform to plunge into a secure, affordable and most importantly, patient safety compliant future.

What are the challenges do you see in the years?

MORE STORIES FROM Bio Spectrum

Bio Spectrum

Bio Spectrum

Navigating the Complexities of Pharma Packaging Sustainability

Pharma companies in India are increasingly adopting sustainable methods in packaging to ensure that medicines remain safe and the environment is protected. Various initiatives by the government, focusing on reducing carbon footprints, are revolutionising the pharma packaging industry.

time to read

8 mins

September 2025

Bio Spectrum

Bio Spectrum

Are BioStartUps in a Funding/Innovation Rut?

At the BioStartUps Founders & Investors Forum 2025, held on August 1, 2025 at the CIDCO Exhibition Centre in Vashi, Navi Mumbai, biotech industry stalwarts deliberated on the country's innovation and startup ecosystem.

time to read

10 mins

September 2025

Bio Spectrum

Bio Spectrum

How Do Recent Deaths Impact Gene Therapy Development?

Cell and gene therapy (CGT) is among the most closely watched areas in pharma and biotech.

time to read

4 mins

September 2025

Bio Spectrum

Bio Spectrum

HealthQuad appoints Namit Chugh as Director

Quadria Group, Asia's leading healthcare-focused private equity platform, has announced the appointment of Namit Chugh as Director at HealthQuad, India's leading healthcare-focused growth venture capital platform.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

Why Is Endoscopy Crucial for Gl Cancer Diagnosis?

The increased demand for gastrointestinal (GI) diagnostics in India, driven by rising disease rates and awareness of early intervention, is not evenly distributed. While major urban hospitals have expanded their endoscopic capabilities, many semi-urban and rural areas face limited access. Addressing this disparity is crucial for extending the benefits of early disease detection across the country.

time to read

4 mins

September 2025

Bio Spectrum

New England Biolabs launches NEBNext low-bias small RNA library prep kit

US-based New England Biolabs (NEB) has announced the launch of the NEBNext Low-bias Small RNA Library Prep Kit, designed to minimise biased representation of small RNA species in sequencing data.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

Qiagen expands NGS portfolio with launch of QIAseq XHYB long read panels

Qiagen has announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

"Awareness and consistent training are needed with the growing demand for effective skin treatments in India"

India’s dermatology and aesthetic market is reportedly among the fastest-growing globally, projected to grow at a CAGR of 10.11 per cent from 2025 to 2032.

time to read

4 mins

September 2025

Bio Spectrum

Dr. Moopen's Legacy Scholarship & Fellowships to aid 25 students from across India

In a path breaking initiative to make medical education accessible to meritorious students and students from economically challenged backgrounds, Padma Shri Dr Azad Moopen, Founder & Chairman of Aster DM Healthcare and a globally recognised philanthropist, has announced an annual scholarship programme Dr. Moopen's Legacy Scholarship & Fellowships Programme aimed at supporting meritorious students seeking admissions in Dr. Moopen's Medical College, Dr Moopen's Nursing College and Dr Moopen's College of Pharmacy in Wayanad, Kerala.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

Iberia Pharma set to open manufacturing unit in India with investment of Rs 70 Cr

Gurugram-based Iberia Pharmaceuticals has announced its new hi-tech manufacturing and research facility spread across 60,000 sq. ft. in Jhajjar, Haryana.

time to read

1 min

September 2025

Translate

Share

-
+

Change font size